This is a news story, published by Yahoo, that relates primarily to Pfizer news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
bladder cancer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest BCG vaccine news, bladder cancer cases news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
antibody treatmentReuters
•81% Informative
Pfizer 's experimental treatment for a type of bladder cancer significantly improved the time patients remained free of certain complications, including cancer recurrence.
Pfizer said it plans to present the data at an upcoming medical meeting and discuss it with global health regulators for a potential approval.
The drug is an anti-PD-1 monoclonal antibody, the same class of treatment as Merck 's Keytruda .
VR Score
91
Informative language
97
Neutral language
67
Article tone
formal
Language
English
Language complexity
67
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links